In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.

Abstract

BACKGROUND The effect of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), a benzoquinone-ansamycin-type Hsp90-inhibitor, on the expression of focal adhesion kinase (FAK) and, when combined with ionizing radiation, on the clonogenicity of prostate cancer cells were determined. MATERIALS AND METHODS FAK was analyzed by Western immunoblot. Prostate carcinoma cells were exposed either to 17-AAG alone or combined with a single radiation fraction of 3 Gy. RESULTS FAK concentrations were reduced by 17-AAG in a time-dependent manner. Treatment with 100 nM 17-AAG for 24 h reduced clonogenicity by 90%. The plot of surviving fraction versus radiation energy dose yielded roughly parallel graphs for solvent- and 17-AAG-treated cells. CONCLUSION 17-AAG induced rapid degradation of FAK A single radiation fraction of 3 Gy did not enhance the dose-dependent drug-effect on survival. In this sequence, the combined effect of both modalities towards clonogenicity was largely additive.

Statistics

0200400200920102011201220132014201520162017
Citations per Year

133 Citations

Semantic Scholar estimates that this publication has 133 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ochel2006InVC, title={In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.}, author={H J Ochel and G{\"{u}nther Gademann}, journal={Anticancer research}, year={2006}, volume={26 3A}, pages={2085-91} }